Published Studies Reveal New Data About Edema Reduction, Patient Satisfaction and Quality of Life With Dayspring System
OAKLAND, Calif.–(BUSINESS WIRE)–Koya Medical, a healthcare company on a mission to transform lymphatic and venous care through a comprehensive suite of innovative, people-centric platforms, today announced two clinical data publications for the treatment of lymphedema and venous disease with its Dayspring® active compression system, including results from the multi-center, randomized, crossover head-to-head trial (NILE) published in the Journal of Vascular Surgery. Results from an open-label study of the Dayspring system for the treatment of lymphedema and venous diseases in the lower extremities were published in Scientific Reports, Nature. The results of the studies will be presented at the American Vein and Lymphatic Society (AVLS) 2022 Annual Congress, being held October 13-16, 2022, in New Orleans, Louisiana. The company also announced that the Centers for Medicare & Medicaid Services (CMS) has confirmed the durable medical equipment (DME) benefit category determination, payment schedule and five final Level II Healthcare Common Procedure Coding System (HCPCS) codes for the Dayspring active compress system in its final biannual Medicare benefit decisions update.
Dayspring is the first non-pneumatic active dynamic compression treatment designed for patient mobility and cleared by the U.S. Food and Drug Administration (FDA) to treat lymphedema and chronic venous conditions.
“The recognition and establishment of the new final CMS HCPCS codes, benefit category determination and payment decision is a significant milestone that provides a new category of options for patients,” said Andy Doraiswamy, Ph.D., Koya Medical founder and CEO. “We are thrilled to expand access to more treatment choices for people living with lymphedema and chronic venous conditions.”